---
title: "Key facts: EMA endorses Sanofi's sleeping sickness treatment; EMS to acquire Medley"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278188930.md"
description: "On February 27, 2026, the European Medicines Agency endorsed Sanofi's Acoziborole Winthrop, a single-dose oral treatment for T.b. gambiense sleeping sickness. Additionally, EMS plans to acquire Sanofi's Medley for over $500 million, pending antitrust approval, aiming to boost EMS's generic market share to 30%, with no plant closures anticipated."
datetime: "2026-03-07T02:03:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278188930.md)
  - [en](https://longbridge.com/en/news/278188930.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278188930.md)
generator: "portal-rs"
---

# Key facts: EMA endorses Sanofi's sleeping sickness treatment; EMS to acquire Medley

-   On February 27, 2026, the European Medicines Agency endorsed Sanofi's Acoziborole Winthrop, a single-dose oral treatment for T.b. gambiense sleeping sickness in patients 12 and older.1
-   EMS plans to acquire Sanofi's Medley for over $500 million, pending antitrust approval. This deal aims to increase EMS's generic market share to 30%, with no plant closures expected.2

### Related Stocks

- [688108.CN](https://longbridge.com/en/quote/688108.CN.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)

## Related News & Research

- [Sanofi (ENXTPA:SAN) Halted Its Phase 3 RSV Vaccine Trial](https://longbridge.com/en/news/297413868.md)
- [Novartis teams with Olympian Laviai Nielsen on MS campaign](https://longbridge.com/en/news/297949471.md)
- [Trulieve highlights 2025 revenue of $1.2 billion in investor presentation](https://longbridge.com/en/news/297783638.md)
- [Illumina (ILMN) Stock Looks Cheap On Cash Flow Yet Pricey On Earnings](https://longbridge.com/en/news/297785097.md)
- [Vaxcyte COO Jim Wassil disposes of USD 254,221.29 in common shares](https://longbridge.com/en/news/297841976.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**